Chart - CYP, page-37

Yes, we've already seen what happens when an Insto buys on market (Fidelity at start of 2018, price more than doubles from $0.60 to $1.40).

We're probably a bit too small (and lack the liquidity) at the moment to get on the radar of most funds.

What we need is the MEND trial to be approved overseas somewhere to give the market a refresh on what Cymerus can do. My best guess is that we would need to average a ~$200M MC (stock price ~$1.70) for 6 months to demonstrate to funds that we are not a fad. Assuming we can, there is every chance the valuation gap between MSB and CYP will be closed from 20:1 to 5:1 or even less.

Obviously there are a few ducks we need to line up, however I am confident we can and have doubled my holding since March.